Epilepsy, Tonic-Clonic Clinical Trial
— XLTCSOfficial title:
XLTCS - Accelerometer Data Collection in an Epilepsy Monitoring Unit (EMU)
NCT number | NCT04282681 |
Other study ID # | LNE-800 |
Secondary ID | |
Status | Withdrawn |
Phase | |
First received | |
Last updated | |
Start date | March 16, 2020 |
Est. completion date | February 28, 2022 |
Verified date | August 2020 |
Source | LivaNova |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The primary objective of this study is to collect accelerometer data from subjects monitored in an EMU with concurrent video EEG.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | February 28, 2022 |
Est. primary completion date | August 28, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 4 Years to 99 Years |
Eligibility |
Inclusion Criteria: 1. Four (4) years of age or older. 2. Admitted to an Epilepsy Monitoring Unit for video EEG monitoring. 3. Based on medical history, expected to have at least one seizure with tonic-clonic convulsive movement during the EMU stay as determined by the investigator. 4. Capable of understanding and willing to comply with instructions and study procedures. 5. Subject or guardian must be willing and able to complete informed consent/assent. Exclusion Criteria: 1. Based on medical history, expected to have only non-epileptic events during the EMU stay as determined by the investigator. 2. Based on medical history, known to have only absence seizures. 3. Medical or psychiatric condition that in the investigator's judgment would prevent the subject's successful completion of the study. 4. Participants with known hypersensitivity or skin sensitivity conditions that will preclude attachment of the accelerometer. 5. Participants who are also taking part in another clinical trial that could confound the results of the study; these patients can be included into the study only if LivaNova has provided written approval. |
Country | Name | City | State |
---|---|---|---|
Belgium | Universitair Ziekenhuis Gent | Ghent |
Lead Sponsor | Collaborator |
---|---|
LivaNova |
Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Evaluate accelerometer data and tonic-clonic seizure data | The study will evaluate accelerometer data and tonic-clonic seizure data that was collected during the patients' EMU admission. The sample size is not based on a statistical power calculation, thus no primary endpoint is defined in the clinical investigation plan. | 1.5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04770337 -
Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy
|
N/A | |
Terminated |
NCT03831802 -
Embrace and Quality of Life
|
N/A | |
Completed |
NCT01439438 -
Topiramate Bioequivalence Study Brazil - Fast
|
Phase 1 | |
Completed |
NCT00150787 -
Monotherapy With Levetiracetam or Carbamazepine in Patients Suffering From Epilepsy.
|
Phase 3 | |
Completed |
NCT00231556 -
A Study on Safety and Efficacy of Two Doses of Topiramate as Monotherapy in the Treatment of Newly Diagnosed or Recurrent Epilepsy
|
Phase 3 | |
Completed |
NCT03446664 -
Microburst Vagus Nerve Stimulator (VNS) Therapy Feasibility Study
|
N/A | |
Completed |
NCT00104416 -
Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Primary Generalized Tonic-Clonic Seizures (PGTC) Seizures
|
Phase 3 | |
Completed |
NCT00043901 -
Treatment Of Primary Generalized Tonic-Clonic Seizures With An Investigational New Drug
|
Phase 4 | |
Completed |
NCT00150813 -
Monotherapy With Levetiracetam in Patients Suffering From Epilepsy.
|
Phase 3 |